TAK-360 for narcolepsy type 2
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests a new medicine called TAK-360 for people with narcolepsy type 2 (narcolepsy without cataplexy). It aims to see if the drug safely reduces daytime sleepiness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must weigh at least 88 pounds (40 kg) and have a BMI between 16 and 38.
- You must have a confirmed diagnosis of narcolepsy type 2 (narcolepsy without cataplexy).
- You cannot have another condition that causes sleepiness, like sleep apnea or depression.
- You cannot have a history of seizures, brain injury, or certain stroke-related conditions.
- You cannot have had cancer (except certain skin cancers) in the last 5 years.
- You must not have an active infection like hepatitis B, hepatitis C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called ALKS 2680 for people with narcolepsy type 2, a condition that causes excessive daytime sleepiness without sudden muscle weakness. The goal is to see if the drug is safe and helps reduce daytime sleepiness.
This trial tests an experimental drug called ORX750 for people with narcolepsy or idiopathic hypersomnia. You would need to stop your current sleepiness medicines to see if ORX750 helps reduce daytime sleepiness.
This is a follow-up study for people who already completed a TAK-360 trial for narcolepsy (a sleep disorder causing sudden sleep attacks) or idiopathic hypersomnia (excessive daytime sleepiness). Researchers want to see if continuing TAK-360 remains safe and effective for you.
This study tests whether a new medication called cleminorexton helps people with narcolepsy (a condition causing severe daytime sleepiness) sleep better and feel more alert. You would take this medication instead of your current narcolepsy drugs for several months to see if it works.
This study looks at people with narcolepsy type 1 or type 2 in Spain to learn more about these conditions. If you or your child has a confirmed diagnosis, you may be able to take part.
This Phase 2/3 study tests TAK-861 in people with narcolepsy type 1 (NT1) who already completed an earlier TAK-861 trial. The goal is to see if the medicine remains safe and effective for ongoing central (brain-related) sleepiness problems.
Hear when a new Narcolepsy Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.